TY - JOUR T1 - MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00074-2016 VL - 3 IS - 1 SP - 00074-2016 AU - Yasmina Bauer AU - Eric S. White AU - Simon de Bernard AU - Peter Cornelisse AU - Isabelle Leconte AU - Adele Morganti AU - Sebastien Roux AU - Oliver Nayler Y1 - 2017/01/01 UR - http://openres.ersjournals.com/content/3/1/00074-2016.abstract N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. The heterogeneity of disease progression in patients with IPF poses significant obstacles to patient care and prevents efficient development of novel therapeutic interventions. Blood biomarkers, reflecting pathobiological processes in the lung, could provide objective evidence of the underlying disease.Longitudinally collected serum samples from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial were used to measure four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor ligand, osteopontin and procollagen type I C-peptide), to assess their potential prognostic capabilities and to follow changes during disease progression in patients with IPF.In baseline BUILD-3 samples, only MMP-7 showed clearly elevated protein levels compared with samples from healthy controls, and further investigations demonstrated that MMP-7 levels also increased over time. Baseline levels of MMP-7 were able to predict patients who had higher risk of worsening and, notably, baseline levels of MMP-7 could predict changes in FVC as early as month 4.MMP-7 shows potential to be a reliable predictor of lung function decline and disease progression.MMP-7 is a predictive biomarker in IPF http://ow.ly/c69Y309aO4R ER -